

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Pharmacology and Therapeutics

**Manuscript NO:** 53831

**Title:** Validation of AJCC 8th Edition of TNM Staging in Resected Distal Pancreatic Cancer

**Reviewer's code:** 03664527

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2019-12-30

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-01-01 02:21

**Reviewer performed review:** 2020-01-03 03:52

**Review time:** 2 Days and 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input checked="" type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input checked="" type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

In terms of ideas and content, this article has Insufficient innovation.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Pharmacology and Therapeutics

**Manuscript NO:** 53831

**Title:** Validation of AJCC 8th Edition of TNM Staging in Resected Distal Pancreatic Cancer

**Reviewer's code:** 03741923

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2019-12-30

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-01-02 15:00

**Reviewer performed review:** 2020-01-06 09:35

**Review time:** 3 Days and 18 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

This is an interesting clinical study with large sample size to validate the American Joint Committee on Cancer (AJCC) 8th edition of TNM staging in distal pancreatic ductal adenocarcinoma (PDAC). Some issues remain to be clarified. 1. Did all patients receive adjuvant chemotherapy after surgery? Are the same chemotherapy treatments, or not? 2. In Table 1, the authors did not provide the information of the treatments after surgery? 3. There are some similar reports (Br J Cancer. 2017 Dec 5;117(12):1874-1882. ), the authors should discuss the difference between these report and this paper.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Pharmacology and Therapeutics

**Manuscript NO:** 53831

**Title:** Validation of AJCC 8th Edition of TNM Staging in Resected Distal Pancreatic Cancer

**Reviewer's code:** 03032964

**Position:** Editorial Board

**Academic degree:** FACS

**Professional title:** Chief Physician, Doctor, Postdoc, Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2019-12-30

**Reviewer chosen by:** Ying Dou

**Reviewer accepted review:** 2020-02-16 16:32

**Reviewer performed review:** 2020-02-17 15:12

**Review time:** 22 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

#### **SPECIFIC COMMENTS TO AUTHORS**

It is a well designed study and quite a lot of cases from different centers were recruited, associating both distribution and risk stratification of the TNM staging system in the 8th edition of AJCC for invasive IPMN and non-IPMN associated PDAC. I have to say it was from a good angle. However, there are a few questions: 1. Since this is a multicenter study, and it is based on the postoperative pathology, there should be an common surgery to be applied among these centers, which however, is not easy to be realized as an inborn drawback for such studies. 2. As for the chemotherapy, which in this study is applied in the None-IMPV group, the chemotherapy protocol should have been well described, should they be identical or what is the evidence for the decision of a certain protocol, eg, the vascular involvement, or the lymphnode. 3. As the for the group of the invasive IPMN, one specific charactor of this type of pancreatic carcinoma in pathology is that the lesions sometimes tend to skip, meaning there might have been some beniegn lesions in between the malignancies, leaving a challenge for ruling them out in the the remnant pancreatic tissue. Also under such circumstance, the determination of the diameter of the lesion, ie, the "T" value as in TNM remains to specifically addressed in this study.